{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031356","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.164827+00:00","generated_at":"2026-05-31T10:04:44.189755+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Azitra Q2 net loss narrows to $2.6M; completes $10M offering, pipeline milestones set","bullets":["Net loss of $2.6M improved from $5.1M in Q2 2023; cash and equivalents $0.8M as of June 30.","Completed $10M follow-on offering, expected to fund operations into 2025.","R&D expenses $1.1M (up from $0.8M); G&A $1.5M (up from $0.8M); service revenue $7,500 (down from $172k).","Expects to dose first Netherton syndrome patient with ATR-12 in Q3 2024; plans IND for ATR-04 for EGFRi rash.","Anticipates initial safety data from ATR-12 Phase 1b by year-end 2024, topline data by mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031356","json":"https://secwatch.observer/filing/0001493152-24-031356.json","markdown":"https://secwatch.observer/filing/0001493152-24-031356.md","text":"https://secwatch.observer/filing/0001493152-24-031356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224031356/0001493152-24-031356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224031356/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:04:44.189755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}